LANTHIO PHARMA
Lanthio Pharma is a privately held drug discovery company that applies its proprietary lanthionine-peptide drug discovery technology LanthioPepTM for the generation of novel peptide therapeutics with increased resistance to peptidase degradation, high receptor specificity and increased intrinsic activity. Lanthio Pharma has generated stable, peptidase-resistant lanthionine peptides with highly specific agonistic activity for a number of GPCR targets, which is a focus area of the company.
LANTHIO PHARMA
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2010-01-01
Address:
Groningen, Groningen, The Netherlands
Country:
The Netherlands
Website Url:
http://www.lanthiopharma.com
Total Employee:
1+
Status:
Active
Contact:
31 50 305 0240
Email Addresses:
[email protected]
Total Funding:
8.4 M EUR
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Hetzner
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
TechnoDerma Medicines
TechnoDerma Medicines is engaged in the research and development of skin drugs for external use.
Current Employees Featured
Founder
Investors List
BioGeneration Ventures
BioGeneration Ventures investment in Series A - Lanthio Pharma
Inkef
Inkef investment in Series A - Lanthio Pharma
Official Site Inspections
http://www.lanthiopharma.com
- Host name: 104.247.82.50
- IP address: 104.247.82.50
- Location: Canada
- Latitude: 43.6319
- Longitude: -79.3716
- Timezone: America/Toronto
More informations about "Lanthio Pharma"
Lanthio Pharma - Crunchbase Company Profile & Funding
Lanthio Pharma is a privately held drug discovery company that applies its proprietary lanthionine-peptide drug discovery technology LanthioPepTM for the generation of novel peptide …See details»
Lanthio Pharma - LinkedIn
With its proprietary technologies, the company is generating lanthionine-constrained peptides with superior target-selectivity and stability. Utilizing our technology we are building a growing...See details»
Lanthio Pharma Company Profile | Management and Employees …
Lanthio Pharma B.V., a wholly owned subsidiary of MophoSys AG since 2015, is a Dutch biopharmaceutical company committed to developing and commercializing therapeutic …See details»
Lanthio Pharma Company Profile - Office Locations, Competitors
It focuses on discovering and developing lantipeptide drugs. Its technology is used as a treatment for fibrosis, stroke, heart failure, and multiple sclerosis. See insights on Lanthio Pharma …See details»
Lanthio Pharma - PitchBook
Operator of a biopharmaceutical company intended to help clients discover and develop therapeutic peptides for severe diseases.See details»
Lanthio Pharma (Lanthipeptide Technology) - PitchBook
Oct 17, 2014 · Information on acquisition, funding, cap tables, investors, and executives for Lanthio Pharma (Lanthipeptide Technology). Use the PitchBook Platform to explore the full …See details»
Lanthio Pharma - VentureRadar
Lanthio Pharma is a biopharmaceutical company focused on discovering and developing stabilized therapeutic peptides, with optimized pharmacological activity. We have developed a …See details»
Lanthio Pharma - Products, Competitors, Financials, Employees ...
Lanthio Pharma is a biopharmaceutical company committed to developing and commercializing therapeutic peptides against difficult to target receptors (e.g. GPCRs). With its proprietary …See details»
Lanthio Pharma - Contacts, Employees, Board Members
Find more contact data in Search! Lanthio Pharma has 1 current employee profile, CEO, Founder and CSO Gert Moll. Lanthio Pharma is focused on the research and development of …See details»
Lanthio Pharma - Funding, Financials, Valuation & Investors
Lanthio Pharma is focused on the research and development of therapeutic lantipeptide drugs for serious diseases.See details»
MorphoSys acquired Lanthio, a Dutch Peptide Therapeutic company
May 8, 2015 · MorphoSys has acquired the Dutch biopharmaceutical company Lanthio Pharma. Morphosys already held 19.98% of Lanthio Pharma and now will pay €20M to purchase all …See details»
MorphoSys Acquires Peptide Therapeutic Company Lanthio Pharma
May 13, 2015 · MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that it has acquired all outstanding shares of the Dutch biopharmaceutical …See details»
MorphoSys acquires Lanthio Pharma - Drug Target Review
May 8, 2015 · MorphoSys has acquired all outstanding shares of the Dutch biopharmaceutical company Lanthio Pharma. The transaction brings Lanthio Pharma’s lead compound LP2, a …See details»
MorphoSys Acquires Lanthipeptide Technology from Lanthio …
Oct 15, 2014 · MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) and Lanthio Pharma today announced the acquisition of Lanthio Pharma`s lanthipeptide …See details»
Dutch and German Biotechs enter the Clinic with their First ...
Feb 22, 2017 · Lanthio Pharma, a Dutch subsidiary of the big German antibody biotechMorphoSys, has initiated its first Phase I trial, making MOR107 MorphoSys’ first …See details»
Gert Moll - CEO, Founder and CSO @ Lanthio Pharma - Crunchbase
Gert Moll is the CEO, Founder and CSO at Lanthio Pharma. There is no recent news or activity for this profile. Gert Moll studied Biology at the University of Utrecht, NL, and did his PhD …See details»
MorphoSys swoops for Lanthio as biotech investment plan matures
May 14, 2015 · MorphoSys (ETR:MOR) has acquired Lanthio Pharma. The deal comes 30 months after MorphoSys originally hooked up with Lanthio, which was the first company to …See details»
MorphoSys Acquires Peptide Therapeutic Company Lanthio Pharma
May 8, 2015 · Acquisition adds novel candidates including Pre-IND candidate for fibrotic diseases to MorphoSys's growing proprietary portfolio.See details»
MorphoSys’ First Lanthipeptide Completes Phase I Successfully
May 19, 2017 · Lanthio Pharma, a Dutch subsidiary of the big German antibody biotech MorphoSys, has initiated its first Phase I trial, making MOR107 MorphoSys’ first lanthipeptide …See details»
LP2, the first lanthipeptide GPCR agonist in a human ... - PubMed
Introduction of a lanthionine into a peptide may enhance target affinity, target specificity and proteolytic resistance.See details»